Biomarker Measurements in Heart Failure With Reduced Ejection Fraction

James Januzzi, MD


November 01, 2022

More than 6.5 million individuals in the United States have heart failure (HF). Early diagnosis coupled with a deeper understanding of the complexity of the syndrome is critical to optimal treatment.

Biomarkers have been used in the diagnosis of HF for decades. However, as precision medicine expands into the field of cardiology, testing of B-type natriuretic peptides (BNPs), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and troponins are now recommended by several major societies as useful diagnostic aids to guide therapy and improve HF outcomes.

Dr James Januzzi, of Massachusetts General Hospital, discusses the emerging applications for biomarkers not only in patients who have been diagnosed with heart failure with reduced ejection fracture, but also for individuals who are currently asymptomatic but are at higher risk for the disease.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.